Iterion Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Iterion Therapeutics, Inc.
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
New bone-targeted agents for osteoporosis must clear significant obstacles to succeed in a highly generic market, but safety concerns with established agents like bisphosphonates and calcitonin offer a foothold. Phase III anabolic candidates from Amgen and Radius Health aim to build new bone, the holy grail of osteoporosis treatment, but R&D in new anti-resorptive mechanisms to halt bone breakdown also continues.
- Other Names / Subsidiaries
- Beta Cat Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.